topsentin has been researched along with oxadiazoles in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auriemma, G; Carbone, D; Cascioferro, S; Cirrincione, G; Cusimano, MG; Deng, D; Di Sarno, V; Diana, P; Giovannetti, E; Musella, S; Parrino, B; Pecoraro, C; Schillaci, D | 1 |
| Avan, A; Carbone, D; Cascioferro, S; Diana, P; Giovannetti, E; Parrino, B; Pecoraro, C; Peters, GJ; Puerta, A | 1 |
2 other study(ies) available for topsentin and oxadiazoles
| Article | Year |
|---|---|
1,2,4-Oxadiazole topsentin analogs as staphylococcal biofilm inhibitors targeting the bacterial transpeptidase sortase A.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Cell Line; Cysteine Endopeptidases; Humans; Imidazoles; Indoles; Oxadiazoles; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 2021 |
A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Catalytic Domain; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Oxadiazoles; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship | 2021 |